Cardiovascular complications after renal transplantation and their prevention
- PMID: 16969281
- DOI: 10.1097/01.tp.0000235527.81917.fe
Cardiovascular complications after renal transplantation and their prevention
Abstract
By the time of renal transplantation, end-stage renal disease patients have a huge burden of cardiovascular disease (CVD) and are heavily saturated with atherosclerotic risk factors. Worsening of preexisting risk factors or new CVD risk factors may develop in the posttransplant period consequent in part to the diabetogenic and atherogenic potential of immunosuppressive drugs. The annual risk of a fatal or non-fatal CVD event of 3.5 to 5% in kidney transplant recipients is 50-fold higher than the general population. Renal allograft dysfunction, proteinuria, anemia, moderate hyperhomocysteinemia and elevated serum C-reactive protein concentrations, each dependently confer greater risk of CVD morbidity and mortality in the posttransplant period. Long-term care of renal transplant recipients should programmatically incorporate the recommendations of the National Kidney Foundation Working Groups and European Best Practice Guidelines Expert Group on Renal Transplantations into the management of hypertension, dyslipidemia, smoking, and posttransplant diabetes mellitus. Timely utilization of coronary revascularization procedures should be undertaken as these treatments are equally effective in the kidney transplant population.
Similar articles
-
[Cardiovascular disease after renal transplantation].G Ital Nefrol. 2004 Jan-Feb;21 Suppl 26:S53-66. G Ital Nefrol. 2004. PMID: 15732047 Review. Italian.
-
Cardiovascular disease after renal transplantation.Semin Nephrol. 2000 Mar;20(2):176-87. Semin Nephrol. 2000. PMID: 10746859 Review.
-
How to decrease cardiovascular mortality in renal transplant recipients.Transplant Proc. 2006 Nov;38(9):2887-92. doi: 10.1016/j.transproceed.2006.08.091. Transplant Proc. 2006. PMID: 17112856
-
Prevalence of risk factors for cardiovascular disease in Brazilian renal transplant recipients.Transplant Proc. 2007 Mar;39(2):446-8. doi: 10.1016/j.transproceed.2007.01.043. Transplant Proc. 2007. PMID: 17362755
-
Risk factors for cardiovascular events after successful renal transplantation.Transplantation. 2008 Jan 27;85(2):209-16. doi: 10.1097/TP.0b013e318160254f. Transplantation. 2008. PMID: 18212625
Cited by
-
New-onset diabetes and glucose regulation are significant determinants of left ventricular hypertrophy in renal transplant recipients.J Diabetes Res. 2015;2015:293896. doi: 10.1155/2015/293896. Epub 2015 Apr 7. J Diabetes Res. 2015. PMID: 25945353 Free PMC article.
-
mTOR inhibition improves mitochondria function/biogenesis and delays cardiovascular aging in kidney transplant recipients with chronic graft dysfunction.Aging (Albany NY). 2021 Mar 23;13(6):8026-8039. doi: 10.18632/aging.202863. Epub 2021 Mar 23. Aging (Albany NY). 2021. PMID: 33758105 Free PMC article.
-
Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review.World J Transplant. 2021 Mar 18;11(3):70-86. doi: 10.5500/wjt.v11.i3.70. World J Transplant. 2021. PMID: 33816147 Free PMC article.
-
The effect of the very low dosage diltiazem on tacrolimus exposure very early after kidney transplantation: a randomized controlled trial.Sci Rep. 2022 Aug 21;12(1):14247. doi: 10.1038/s41598-022-18552-7. Sci Rep. 2022. PMID: 35989346 Free PMC article. Clinical Trial.
-
BP targets in renal transplant recipients: too high or too low?J Am Soc Nephrol. 2014 Jul;25(7):1371-3. doi: 10.1681/ASN.2014020177. Epub 2014 Mar 13. J Am Soc Nephrol. 2014. PMID: 24627350 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials